According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer. Certain features may make patients ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...

The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations. Patients with non–small cell lung cancer (NSCLC) who have uncommon EGFR mutations appear to have ...

In a recent study published in The Lancet Regional Health-Southeast Asia, researchers developed an artificial intelligence (AI)-based predictive system (AIPS) model for the early detection of lung ...

Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized ...

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...

Financial Guidance As of September 30, 2025, cash, cash equivalents and investments totaled $413.0 million, which the company expects will be sufficient to fund its operating plan into 2H 2028, beyond ...

Equity for under-served populations in lung cancer screening and treatment: Does mobile low-dose CT scanning lead to stage shift and diagnosis with potential cures at 4 years of follow-up? Summary of ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...